Will Insurance or a Government Scheme — Pay for Abiraterone?

First check whether your hospital is on the PM-JAY network for cancer treatment — not all empanelled hospitals are approved for all procedures. If the hospital is on the network and your card is still being declined, contact the State Health Agency for your state: in Telangana, the Aarogyasri Health Care Trust; in Andhra Pradesh, the Dr. YSR Aarogyasri Trust. They can verify your beneficiary status and intervene if the card is being incorrectly rejected. Keep a record of every call: who you spoke to, the date, and what was said.

Ask your oncologist to write a letter explaining why abiraterone is the medically appropriate treatment for your specific situation — insurers have a formal appeals process and a clinical justification letter is usually the first requirement. Submit a written appeal rather than relying on a phone call, and keep copies of everything you send and receive. If the appeal is rejected, ask whether a different formulation or a generic version might qualify under the policy wording. A health insurance ombudsman is available in India if you believe a valid claim has been wrongly refused.

Yes. Generic abiraterone contains the same active molecule as the originator product and is approved by the Central Drugs Standard Control Organisation (CDSCO) for the same use. The difference is price, not efficacy or safety profile. Your oncologist can confirm whether a specific generic is appropriate for your treatment plan and advise on the correct formulation. Any switch between originator and generic, or between generics, should happen with your oncologist's involvement rather than independently.

It depends on your scheme. Under cashless schemes such as PM-JAY and Aarogyasri, the drug is typically dispensed through the network hospital. Under CGHS, collection from a CGHS-approved pharmacy is usually possible. If you are paying privately or seeking reimbursement, you can generally buy from any licensed pharmacy, but keep all original receipts and the prescription. Ask the billing team at your treating hospital before your first purchase to avoid buying from somewhere that creates a problem for your claim later.

Sometimes — a process called coordination of benefits allows a second payer to cover costs the first did not. In practice, CGHS has specific rules about how it interacts with other plans, and many private insurers require CGHS to be used first. Ask both the CGHS office and your private insurer to explain their rules in writing before assuming one will top up the other. The hospital billing team may have practical experience with this combination and can advise on the sequence most likely to succeed.

Ask for the rejection in writing with the specific reason stated. Common reasons include the drug not being on the approved list, incomplete documentation, or the request going to the wrong department. Your oncologist can help address each of these — a clinical justification letter for a drug eligibility dispute, a corrected submission for a documentation issue. You have the right to appeal a rejection formally. Do not start buying the drug on credit while waiting for an appeal outcome — reimbursement after a rejected authorisation is not guaranteed.